GSK 6-K
GSK plc (GSK)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2024
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc
GSK publishes provisional dividend dates
GSK announces the following dividend dates for 2025:
These dates are indicative and may be subject to change.
| Results | Announcement date | Ordinary Shares<br><br><br>Ex-dividend date | American Depositary Shares<br><br><br>Ex-dividend date | Record date | Last date for DRIP elections | Payable |
|---|---|---|---|---|---|---|
| Q1 2025 | Wednesday 30 April 2025 | Thursday 15 May 2025 | Friday 16 May 2025 | Friday 16 May 2025 | Thursday 19 June 2025 | Thursday 10 July 2025 |
| Q2 2025 | Wednesday 30 July 2025 | Thursday 14 August 2025 | Friday 15 August 2025 | Friday 15 August 2025 | Thursday 18 September 2025 | Thursday 9 October 2025 |
| Q3 2025 | Wednesday 29 October 2025 | Thursday 13 November 2025 | Friday 14 November 2025 | Friday 14 November 2025 | Monday 15 December 2025 | Thursday 8 January 2026 |
| Q4 2025 | Wednesday 4 February 2026 | Thursday 19 February 2026 | Friday 20 February 2026 | Friday 20 February 2026 | Tuesday 17 March 2026 | Thursday 9 April 2026 |
V A Whyte
Company Secretary
11 November 2024
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
|---|---|
| (Registrant) | |
| Date: November<br>11, 2024 | |
| By:/s/ VICTORIA<br>WHYTE<br><br><br>-------------------------- | |
| Victoria Whyte | |
| Authorised<br>Signatory for and on | |
| behalf<br>of GSK plc |